Latest Hotspot

Sensei Biotherapeutics presents positive trial results for SNS-101 at SITC Conference 2023

14 November 2023
3 min read

Clinical development immuno-oncology company, Sensei Biotherapeutics, Inc., which concentrates on discovering and creating the forthcoming generation treatments for cancer patients, unveiled early results from the lone therapy dose-increase segment of its Phase 1/2 clinical research for SNS-101, a selectively active, human monoclonal antibody directed at the immune checkpoint VISTA.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The information, set to be revealed during a late-breaker poster session at the Society for Immunotherapy of Cancer 38th Annual Meeting, suggests an optimal safety and pharmacokinetic profile among VISTA-blocking antibodies. It also indicates the capability to tackle long-term pharmacological problems that the first generation of VISTA-blocking methodologies have faced.

John Celebi, CEO and President of Sensei Biotherapeutics, expressed his gratification over the promising clinical data for SNS-101, a revolutionary VISTA-blocking antibody which proves the effectiveness of their conditionally active methodology. 

The details affirm e that this innovative antibody handled all current dosage levels without complications, shows dose-dependent linear pharmacokinetics expected preclinically to cause immune system-controlled anti-tumor activity, along with a cytokine profile consistent with no occurrence of cytokine release syndrome.

John Celebi further explained that the clinical study data so far provides significant initial proof that SNS-101 may provide clinically significant and mechanistic distinction from first generation anti-VISTA methods. This is signified by SNS-101 dosage levels which are at least 10 times higher than the first clinical study of a competing VISTA antibody that was abruptly stopped due to cytokine release syndrome and unfavorable pharmacokinetics.

The multi-center Phase 1/2 clinical trial is being conducted to assess SNS-101’s safety, tolerance, pharmacokinetics, pharmacodynamics, and efficacy as a single and in conjunction with Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab) in patients with advanced solid tumors.

Medical oncologist at NEXT Oncology, Shiraj Sen, M.D., Ph.D., said he was optimistic about the SNS-101 trial's patient experience so far, as it shows a potential leading safety profile and a tri-weekly dosage plan, which eases the logistical strain that agents that require more frequent administration usually place on patients, due to their unfavorable pharmacokinetics.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of November 12, 2023, there are 17 investigational drugs for the VISTA target, including 28 indications, 24 R&D institutions involved, with related clinical trials reaching 11 and as many as 8429 patents.

With its wide range of active indications, SNS-101 has the potential to address multiple therapeutic areas. However, as it is currently in Phase 1/2 of clinical development, further research and testing are needed to fully understand its safety and efficacy profile.

图形用户界面, 文本, 应用程序

描述已自动生成

What are AMPK inhibitors and how do you quickly get the latest development progress?
What are AMPK inhibitors and how do you quickly get the latest development progress?
14 November 2023
AMPK is a critical metabolic regulator, responsible for maintaining and restoring energy balance at the cellular and physiological levels. Studying AMPK targets and their microenvironment helps clarify how AMPK restores energy homeostasis.
Read →
BDC-1001: Brief Review of its R&D progress and the clinical outcome in 2023 ESMO
ESMO 2023
4 min read
BDC-1001: Brief Review of its R&D progress and the clinical outcome in 2023 ESMO
13 November 2023
On October 20, 2023, the first-in-human trial of BDC-1001 in advanced HER2-positive solid tumors was reported at the ESMO Congress.
Read →
REGENXBIO shares encouraging one-year results from Phase II ALTITUDE trial, using ABBV-RGX-314 for addressing Diabetic Retinopathy through Suprachoroidal Delivery
Latest Hotspot
3 min read
REGENXBIO shares encouraging one-year results from Phase II ALTITUDE trial, using ABBV-RGX-314 for addressing Diabetic Retinopathy through Suprachoroidal Delivery
13 November 2023
REGENXBIO Inc. reveals positive additional results from ongoing Phase II ALTITUDE® study. The study pertains to ABBV-RGX-314, expected for treating diabetic retinopathy except center-involved diabetic macular edema, and is given through in-office suprachoroidal delivery.
Read →
What are Akt inhibitor and how do you quickly get the latest development progress?
What are Akt inhibitor and how do you quickly get the latest development progress?
13 November 2023
AKT (Protein Kinase B), a pivotal player in PI3K/AKT/m-TOR signaling pathway, is a prospective drug target clinically. Its activation is crucial for cell survival and growth, implicating in tumorigenesis and metastasis. Research indicates AKT over-activation in over 50% of tumors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.